Tivozanib

Tivozanib functions as a tyrosine kinase inhibitor, a class of drugs that target specific signaling pathways involved in cancer cell growth and proliferation. By inhibiting tyrosine kinases, tivozanib interferes with the abnormal cell division and survival characteristic of cancer.

Adult

BY MOUTH: 1340 micrograms once daily for 21 consecutive days of repeated 28 day cycles. For dose adjustments due to side effects, consult product literature.

Hepatic adjustment

Caution in mild-to-moderate impairment—monitor patients for tolerability; avoid in severe impairment. Reduce dose to 1340 micrograms on alternate days in moderate impairment—increased risk of adverse effects due to increased exposure.

• History of arterial thromboembolic events
• History of bleeding disorders
• History of posterior reversible encephalopathy syndrome following tivozanib treatment
• History of QT-interval prolongation
• History of venous thromboembolic events
• Major surgical procedures (interrupt treatment)
• Patients aged over 65 years (increased risk of adverse effects)
• Pre-existing cardiac disease
• Risk factors for arterial thromboembolic events
• Risk factors for gastro-intestinal fistula
• Risk factors for gastro-intestinal perforation
• Risk factors for venous thromboembolic events
• Risk of bleeding